Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Chinese Patent Office
UBS
Moodys
Novartis
Colorcon
Dow
Farmers Insurance
Deloitte
Johnson and Johnson

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,395,970

« Back to Dashboard

Summary for Patent: 5,395,970
Title: 1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol
Abstract:Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.
Inventor(s): Tuttle; Ronald R. (Escondido, CA), Browne, III; Clinton E. (Oceanside, CA)
Assignee: Gensia Pharmaceuticals, Inc. (San Diego, CA)
Application Number:08/169,536
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 5,395,970

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,395,970

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 129644 ➤ Try a Free Trial
Austria 159710 ➤ Try a Free Trial
Australia 3008889 ➤ Try a Free Trial
Australia 634152 ➤ Try a Free Trial
Germany 68924661 ➤ Try a Free Trial
Germany 68928422 ➤ Try a Free Trial
Denmark 73589 ➤ Try a Free Trial
European Patent Office 0329464 ➤ Try a Free Trial
European Patent Office 0658538 ➤ Try a Free Trial
Spain 2081299 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chubb
Federal Trade Commission
Chinese Patent Office
Merck
Express Scripts
Fuji
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot